April 12th 2024
Data showed that 87.8% of treated patients and 96.1% of patients who completed the study achieved normal 24-hour mean plasma testosterone values (222 to 800 ng/dL) at 90-day follow-up.
September 28th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Product Update: HIFU cleared, compact catheter launched
November 1st 2015Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.
Case study: Discomfort, swelling in groin
This slideshow presents a case study of a 30-year-old male with discomfort in left groin region due to mass/swelling for 1 year.
Fusion biopsy increases detection of high-grade PCa
October 1st 2015New study findings from the Ronald Reagan UCLA Medical Center, Los Angeles add evidence supporting the potential for targeted magnetic resonance-ultrasound (MR-US) fusion biopsy to improve the diagnosis of prostate cancer. Learn more
Abiraterone/low-dose prednisone show efficacy in PCa
October 1st 2015Phase II study results show that daily treatment with abiraterone acetate (ZYTIGA), 1,000 mg, plus prednisone, 5 mg was very effective in lowering PSA levels in men with non-metastatic castrate-resistant prostate cancer (CRPC) at high risk for metastasis. Learn more
Imaging tool shows accuracy for lymph node staging
October 1st 2015Positron emission tomography with a 68Gallium-labeled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA-PET hybrid imaging) is a promising new diagnostic tool for staging prostate cancer, according to German urologists who presented their experience at the American Society of Clinical Oncology annual meeting in Chicago. Get results
Shock wave therapy found efficacious in treating ED
October 1st 2015Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.
Advanced prostate cancer: Why men aren’t speaking up
October 1st 2015Hear and get results from Neal Shore, MD, as he discusses with Crystal Murcia, PhD the surveys findings, explains why men aren’t speaking up about their prostate cancer symptoms, and urologists' role in assessing how patients are feeling.
How a young urologist can start a career in men's health
September 1st 2015The opportunities for physicians in men’s health are tremendous. As with most career moves, blindly entering a field is ill advised. Rather, I recommend that the thoughtful young urologist carefully consider the following steps and pointers.
BPH modality may offer efficient option
September 1st 2015A novel treatment for the targeted removal of prostate tissue may soon be coming to a hospital near you. According to the results of a phase II study presented at the AUA annual meeting in New Orleans, Aquablation, a minimally invasive water ablation therapy, demonstrated efficient and precise resection of prostate tissue in patients with BPH.
Study: BPH procedure’s benefits sustained at 3 years
September 1st 2015The prostatic urethral lift (PUL [UroLift, NeoTract, Inc.]) yields successful 3-year durability and superior rate of improvement of BPH symptoms compared to transurethral resection of the prostate, according to separate studies presented at the AUA annual meeting in New Orleans.
TRT not associated with thrombotic events in older men
September 1st 2015The association between testosterone replacement therapy (TRT) and thrombotic risk in elderly men remains controversial. While the FDA has mandated that all approved testosterone products include warnings about a possible increase in cardiovascular, stroke, and venous blood clot risk, at least one study presented at the AUA annual meeting in New Orleans found no link between TRT and cardiovascular events.